ROYALTY PHARMA PLC- CL A (RPRX:NASDAQ)
$54.48 0.51 (0.945%)
Analysed ROYALTY PHARMA PLC- CL A (RPRX:NASDAQ) News Sources
Royalty Pharma to present at upcoming investor conferences
07-05-2026
yahoo.com
10% Of This Royalty Pharma Insider's Holdings Were Sold
08-05-2026
yahoo.com
This Fund Cashed Out of Preformed Line Products Amid a 150% Stock Surge
08-05-2026
fool.com
Why One Fund’s $4 Million Centerra Gold Exit Looks Like Profit-Taking Amid a 150% Rally
10-05-2026
fool.com
Income Investors Should Know That Royalty Pharma plc (NASDAQ:RPRX) Goes Ex-Dividend Soon
11-05-2026
yahoo.com
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
12-05-2026
yahoo.com
Royalty Pharma’s Q1 Earnings Call: Our Top 5 Analyst Questions
16-05-2026
yahoo.com
Royalty Pharma (RPRX) Benefits from Biotech Funding Gap with Rising Returns and Market Dominance
18-05-2026
yahoo.com
3 Mid-Cap Stocks We Steer Clear Of
20-05-2026
yahoo.com
Royalty Pharma (RPRX) Valuation Check After Strong Share Price Momentum And Royalty Growth Potential
25-05-2026
yahoo.com
What is the current price of ROYALTY PHARMA PLC- CL A (RPRX:NASDAQ)?
The current price of ROYALTY PHARMA PLC- CL A (RPRX:NASDAQ) is $54.48.
ROYALTY PHARMA PLC- CL A (RPRX:NASDAQ) absolute price change since previous trading day?
The absolute price change of ROYALTY PHARMA PLC- CL A (RPRX:NASDAQ) since the previous trading day is $0.51.
ROYALTY PHARMA PLC- CL A (RPRX:NASDAQ) percentage price change since previous trading day?
The percentage price change of ROYALTY PHARMA PLC- CL A (RPRX:NASDAQ) since the previous trading day is 0.945%.
What is the most recent average sentiment score for ROYALTY PHARMA PLC- CL A (RPRX:NASDAQ)?
The most recent average sentiment score for ROYALTY PHARMA PLC- CL A (RPRX:NASDAQ) is 70 out of 100.
What is the most recent average sentiment for ROYALTY PHARMA PLC- CL A (RPRX:NASDAQ)?
The most recent sentiment for ROYALTY PHARMA PLC- CL A (RPRX:NASDAQ) is .
SEC-8K** Filing Available For ROYALTY PHARMA PLC- CL A (RPRX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.